|Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group|
|Kim, Seok Jin1; Hsu, Chiun2; Song, Yu-Qin3; Tay, Kevin4; Hong, Xiao-Nan5; Cao, Junning5; Kim, Jin Seok6; Eom, Hyeon Seok7; Lee, Joon Hyeok8; Zhu, Jun9; Chang, Kian-Meng10; Reksodiputro, Arry Harryanto11; Tan, Daryl12; Goh, Yeow Tee12; Lee, Jejung13; Intragumtornchai, Tanin14; Chng, Wee-Joo15; Cheng, Ann-Lii2; Lim, Soon Thye4; Suh, Cheolwon16; Kwong, Yok-Lam17; Kim, Won Seog1|
|关键词||Hepatitis B virus Rituximab B-cell Lymphoma|
|刊名||EUROPEAN JOURNAL OF CANCER|
|WOS标题词||Science & Technology|
|关键词[WOS]||HBSAG-NEGATIVE PATIENTS ; CYTOTOXIC CHEMOTHERAPY ; HBV REACTIVATION ; CANCER-PATIENTS ; RISK-FACTORS ; SYSTEMIC CHEMOTHERAPY ; PREEMPTIVE LAMIVUDINE ; MALIGNANT-LYMPHOMA ; PROSPECTIVE COHORT ; THERAPY|
Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas.
Methods: Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis.
Results: HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p < 0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p < 0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases.
Conclusions: This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. (C) 2013 Elsevier Ltd. All rights reserved.
|作者单位||1.Ampang Hosp, Dept Hematol, Selangor, Malaysia|
2.Singapore Gen Hosp, Dept Haematol, Singapore, Singapore
3.Asan Med Ctr, Dept Oncol, Seoul, South Korea
4.Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 135710, South Korea
5.Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
6.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Beijing 100871, Peoples R China
7.Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
8.Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
9.Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol, Seoul, South Korea
10.Natl Canc Ctr, Hematol Malignancy Branch, Gyeonggi Do, South Korea
11.Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol,Dept Med, Seoul, South Korea
12.Peking Univ, Dept Med, Canc Hosp, Beijing 100871, Peoples R China
13.Cipto Mangunkusumo Gen Hosp, Dept Internal Med, Div Hematol Oncol, Jakarta, Indonesia
14.Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Jeollanam Do, South Korea
15.Chulalongkorn Univ, Dept Med, Div Hematol, Bangkok, Thailand
16.Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore, Singapore
17.Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
|Kim, Seok Jin,Hsu, Chiun,Song, Yu-Qin,et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group[J]. EUROPEAN JOURNAL OF CANCER,2013,49(16):3486-3496.|
|APA||Kim, Seok Jin.,Hsu, Chiun.,Song, Yu-Qin.,Tay, Kevin.,Hong, Xiao-Nan.,...&Kim, Won Seog.(2013).Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group.EUROPEAN JOURNAL OF CANCER,49(16),3486-3496.|
|MLA||Kim, Seok Jin,et al."Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group".EUROPEAN JOURNAL OF CANCER 49.16(2013):3486-3496.|
|[Kim, Seok Jin]的文章|
|[Kim, Seok Jin]的文章|
|[Kim, Seok Jin]的文章|